ClpC2 protects mycobacteria against a natural antibiotic targeting ClpC1-dependent protein degradation
暂无分享,去创建一个
[1] I. Sinning,et al. Antibacterial peptide CyclomarinA creates toxicity by deregulating the Mycobacterium tuberculosis ClpC1–ClpP1P2 protease , 2022, The Journal of biological chemistry.
[2] S. Abd ElHafeez,et al. A systematic review and meta-analysis of the catastrophic costs incurred by tuberculosis patients , 2022, Scientific reports.
[3] J. Nachega,et al. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[4] Ryan R. Chaparian,et al. Promoter Pull-Down Assay: A Biochemical Screen for DNA-Binding Proteins. , 2020, Methods in molecular biology.
[5] M. Kaswa,et al. Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study , 2020, PloS one.
[6] D. Oh,et al. Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions , 2020, Acta crystallographica. Section D, Structural biology.
[7] G. Taylor,et al. Genome‐wide interaction screen for Mycobacterium tuberculosis ClpCP protease reveals toxin–antitoxin systems as a major substrate class , 2020, The FEBS journal.
[8] Kamila B. Franke,et al. Toxic Activation of an AAA+ Protease by the Antibacterial Drug Cyclomarin A. , 2019, Cell chemical biology.
[9] T. Akopian,et al. Pyrazinamide triggers degradation of its target aspartate decarboxylase , 2019, Nature Communications.
[10] C. Abad-Zapatero,et al. High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads. , 2019, ACS infectious diseases.
[11] K. Turgay,et al. Xenogeneic modulation of the ClpCP protease of Bacillus subtilis by a phage-encoded adaptor-like protein , 2019, The Journal of Biological Chemistry.
[12] Wei-Lin Gao,et al. Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus , 2019, Antimicrobial Agents and Chemotherapy.
[13] T. Clark,et al. Understanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosis , 2018, Scientific Reports.
[14] Reidar Andreson,et al. Primer3_masker: integrating masking of template sequence with primer design software , 2018, Bioinform..
[15] Julien Vaubourgeix,et al. Targeting the Proteostasis Network for Mycobacterial Drug Discovery , 2018, ACS infectious diseases.
[16] K. Węgrzyn,et al. Handcuffing reversal is facilitated by proteases and replication initiator monomers , 2017, Nucleic acids research.
[17] K. Mechtler,et al. Arginine phosphorylation marks proteins for degradation by a Clp protease , 2016, Nature.
[18] M. Hibberd,et al. Transcriptional Profiling of Mycobacterium tuberculosis Exposed to In Vitro Lysosomal Stress , 2016, Infection and Immunity.
[19] K. Lewis,et al. High Persister Mutants in Mycobacterium tuberculosis , 2016, PloS one.
[20] Itay Mayrose,et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules , 2016, Nucleic Acids Res..
[21] M. Schirle,et al. Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of Action , 2015, Chembiochem : a European journal of chemical biology.
[22] Robert H. Vass,et al. A Phosphosignaling Adaptor Primes the AAA+ Protease ClpXP to Drive Cell Cycle-Regulated Proteolysis. , 2015, Molecular cell.
[23] Eilika Weber-Ban,et al. The Mycobacterium tuberculosis ClpP1P2 Protease Interacts Asymmetrically with Its ATPase Partners ClpX and ClpC1 , 2015, PloS one.
[24] Suhair Sunoqrot,et al. The Cyclic Peptide Ecumicin Targeting ClpC1 Is Active against Mycobacterium tuberculosis In Vivo , 2014, Antimicrobial Agents and Chemotherapy.
[25] S. Waddell,et al. Potassium availability triggers Mycobacterium tuberculosis transition to, and resuscitation from, non-culturable (dormant) states , 2014, Open Biology.
[26] Alfred Goldberg,et al. Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. , 2014, Chemistry & biology.
[27] D. Brodersen,et al. VapC20 of Mycobacterium tuberculosis cleaves the Sarcin–Ricin loop of 23S rRNA , 2013, Nature Communications.
[28] Srinivasa P. S. Rao,et al. Structural Basis of Mycobacterial Inhibition by Cyclomarin A , 2013, The Journal of Biological Chemistry.
[29] Philip R. Evans,et al. How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.
[30] Itay Mayrose,et al. ConSurf: Using Evolutionary Data to Raise Testable Hypotheses about Protein Function , 2013 .
[31] A. Goldberg,et al. The active ClpP protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring , 2012, The EMBO journal.
[32] P. Zwart,et al. Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.
[33] A. Goldberg,et al. Mycobacterium tuberculosis ClpP1 and ClpP2 Function Together in Protein Degradation and Are Required for Viability in vitro and During Infection , 2012, PLoS pathogens.
[34] Slawomir Kubik,et al. Opposing effects of DNA on proteolysis of a replication initiator , 2011, Nucleic acids research.
[35] B. Raynal,et al. Assembly and proteolytic processing of mycobacterial ClpP1 and ClpP2 , 2011, BMC Biochemistry.
[36] Thomas R. Ioerger,et al. High-Resolution Phenotypic Profiling Defines Genes Essential for Mycobacterial Growth and Cholesterol Catabolism , 2011, PLoS pathogens.
[37] T. Baker,et al. The ClpS adaptor mediates staged delivery of N-end rule substrates to the AAA+ ClpAP protease. , 2011, Molecular cell.
[38] P. Niyomrattanakit,et al. The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. , 2011, Angewandte Chemie.
[39] E. Rubin,et al. Characterization and Transcriptome Analysis of Mycobacterium tuberculosis Persisters , 2011, mBio.
[40] Tal Pupko,et al. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids , 2010, Nucleic Acids Res..
[41] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[42] Wolfgang Kabsch,et al. Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.
[43] Zeljka Maglica,et al. Clp chaperone-proteases: structure and function. , 2009, Research in microbiology.
[44] G. Sheldrick,et al. Crystallographic ab initio protein structure solution below atomic resolution , 2009, Nature Methods.
[45] H. Mollenkopf,et al. M. tuberculosis Gene Expression during Transition to the "Non-Culturable" State , 2009, Acta naturae.
[46] F. Striebel,et al. Controlled destruction: AAA+ ATPases in protein degradation from bacteria to eukaryotes. , 2009, Current opinion in structural biology.
[47] Deepa Sikriwal,et al. Mycobacterium tuberculosis ClpC1 , 2008, The FEBS journal.
[48] Randy J. Read,et al. Dauter Iterative model building , structure refinement and density modification with the PHENIX AutoBuild wizard , 2007 .
[49] Deepa Sikriwal,et al. Characterization and role of the N-terminal domain in its function , 2008 .
[50] K. Henrick,et al. Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.
[51] W. Houry,et al. ClpP: A distinctive family of cylindrical energy‐dependent serine proteases , 2007, FEBS letters.
[52] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[53] S. Lawn,et al. Extensively drug resistant tuberculosis , 2006, BMJ : British Medical Journal.
[54] Janine Kirstein,et al. Adaptor protein controlled oligomerization activates the AAA+ protein ClpC , 2006, The EMBO journal.
[55] B. Bukau,et al. Targeted delivery of an ssrA-tagged substrate by the adaptor protein SspB to its cognate AAA+ protein ClpX. , 2003, Molecular cell.
[56] A. Horwich,et al. ClpS, a substrate modulator of the ClpAP machine. , 2002, Molecular cell.
[57] J. Betts,et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.
[58] William Fenical,et al. Cyclomarins A—C, New Antiinflammatory Cyclic Peptides Produced by a Marine Bacterium (Streptomyces sp.). , 2000 .
[59] William Fenical,et al. Cyclomarins A−C, New Antiinflammatory Cyclic Peptides Produced by a Marine Bacterium (Streptomyces sp.) , 1999 .
[60] A. Horwich,et al. Chaperone rings in protein folding and degradation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[61] A. Horwich,et al. Global unfolding of a substrate protein by the Hsp100 chaperone ClpA , 1999, Nature.
[62] C. Larsen,et al. Protein Translocation Channels in the Proteasome and Other Proteases , 1997, Cell.
[63] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.